David Olmeda

Investigador Principal. (IIBm-CSIC)
Uno de esos locos empeñados en curar el cancer.

[Guillermo de Cárcer @GdC_CCCB_lab]

Curiosity driven science!!!
CURIOSITY 👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼

[David Olmeda @Dolmeda]

@thsottiaux My usage went from 47% to 0, then back to 46% , the back to 0 again and still not responding on OpenClaw. But it's ok if I use work. This is nuts!

[David Olmeda @Dolmeda]

@thsottiaux My account went from 43% to 0 in 1 second, then came back to 43% a while after and back to 0 minutes after. Something is going very wrong with Openai.

[Nature Medicine @NatureMedicine]

Multi‑scale modelling shows that measles transmission at the school level in the United States crossed the epidemic threshold after 2022–23, a shift not detectable by county‑ or district‑level surveillance.
https://t.co/5vAtvjqWLx

[Anthropic @AnthropicAI]

We support this petition, signed by our CEO, several co-founders, and senior staff.

Our own research on recursive self-improvement, published last month, points to the need for tools to deliberately pace the frontier of AI development so society can prepare. We’re glad to see broad agreement across the field. https://t.co/DqwuQfa9xH

[Jesus Perez Gil @birloque]

Querido Secr. de Estado, ante todo, muchas gracias por la molestia de escribir esa tribuna alegando a nuestra llamada a un crecimiento mucho más potente de lo que se alardea de los Proyectos de Generación de Conocimiento.
Según ud. estamos fenomenal y progresamos adecuadamente.
Permítame que para responder a su ofensa de que hablamos sin rigor científico le explique un poco mejor en este hilo lo que no ha querido, o no le ha convenido, entender de nuestra tribuna.

[David Olmeda @Dolmeda]

¿Qué ciencia puede realizarse con 50.000 euros al año? https://t.co/MC5wgMtOqv vía @el_pais

[Daniela Cerezo Wallis @danielacerezo]

I’m thrilled to introduce you to the NeuMap! our latest work in @Nature. A global, comprehensive, single-cell transcriptional atlas of neutrophils across 47 biological conditions in human and mice. A real tour-de-force 🗺️ @AndrsHidalgo16 https://t.co/W8X6eOUsKc

[IIBM @IIBmCSICUAM]

📢 Si te gustan los juegos de mesa y quieres aprender sobre ciencia tienes el plan perfecto para el sábado 22/11 en @MecatolRex

👉Científic@s del #IIBM y del @CIB_CSIC explicarán los juegos a l@s asistentes

¡No te lo pierdas!

Más info:👇
https://t.co/PN1nP1ZqAi
@CSICdivulga

[Christoph Bock Lab @ CeMM & MedUni Vienna @BockLab]

🗨️ Just published in @NatureBiotech: Our CellWhisperer AI enables chat-based analysis of single-cell sequencing data. You can talk to your cells & figure out the biology without writing any computer code. Paper link and annotated walkthrough in the thread below (1/11)

[David Olmeda @Dolmeda]

@SanchoLab @GdC_CCCB_lab @IIBmCSICUAM Thanks to you David @Sancholab m it has been an honor and a pleasure having you amount us.

[IIBM @IIBmCSICUAM]

🌞 Day 2 begins at La Cristalera!

Today we welcome 2 Invited Plenary Speakers:
🔶 Prof. David Sancho, @SanchoLab @CNIC_CARDIO
🔶 Prof. Susana Guerrero Salazar, @IGIUMAoficial (University of Málaga @InfoUMA )

Another full day of science, ideas, and inspiring talks ahead! ✨

[IIBM @IIBmCSICUAM]

🏆 Nos alegra compartir que la Fundación Banco de Alimentos de Madrid @bancoalimadrid premia al #IIBM por su colaboración continuada durante años

Un reconocimiento que nos motiva a seguir apoyando iniciativas solidarias y de compromiso social 🙌

👉 Gracias al Servicio Genómica

[IIBM @IIBmCSICUAM]

🚀 New article published by Maria Alieva's group @imaigenelab at the #IIBmCSICUAM
👉 https://t.co/zTqJOyL5oQ
Congratulations !!👏👏

[imAIgene LAB @imaigenelab]

How do cancer cells behave in their natural 3D environments?
Our new tool, BEHAV3D-TP, enables researchers to analyze single-cell behavioral heterogeneity — revealing distinct cancer invasion patterns and their relationships with the TME.
Developed with @Dream3DLab 🔬 👇

[David Olmeda @Dolmeda]

@Nufediaz @embl @EuroBioImaging Wow! Enhorabuena!

[CNIO Stop Cancer @CNIOStopCancer]

El CNIO y Highlight Therapeutics prueban un compuesto contra el cáncer de piel más frecuente, el carcinoma basocelular. @msmelanoma y @MSol_Quintero explican el nuevo ensayo clínico para demostrar la eficacia del compuesto BO-112. Financia @CienciaGob 

 https://t.co/YHKFL5YQIV

[Iván Márquez Rodas 🇪🇦 @ivanpantic1980]

Happy to share the final results of the 🇪🇸 & 🇫🇷 ph2 trial of intratumoral BO-112 + pembro for patients with anti PD-1 resistant #melanoma. 25% ORR and 54% patients alive at 2 years. 16 years of basic and clinical research behind. Some context here 👇🧵

https://t.co/FliIWbTKcw

[Dr. Patrick Hwu @PatrickHwuMD]

#ScienceSaturday

➡️ Melanoma secretes a protein called midkine (MDK), which plays a key role in reprogramming dendritic cells in the tumor microenvironment.

❓ How can this impact immune responses?

➡️ In this study by @msmelanoma et al., MDK was shown to induce immune suppression by altering dendritic cell function. This impaired the ability of the immune system to effectively target and eliminate melanoma cells, allowing the tumor to progress.

➡️ Targeting MDK in preclinical models restored dendritic cell function, enhanced the activation of cytotoxic T cells, and improved antitumor immune responses.

🌟 This study suggests that inhibiting MDK could be a valuable strategy to improve immunotherapy outcomes in melanoma!

🔗 Here’s a link to the full study: https://t.co/5ohl7WwokC

@NatureCancer

[Jorge Martínez Torrecuadrada @JTorrecuadrada]

Thrilled to celebrate this award, recognizing the outstanding work of our multidisciplinary team on the use of antibodies in developing effective strategies for cancer management. Congrats to all team members!